Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Penumbra, Inc. on Its Follow-On Offering
Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 1,495,000 shares of common stock for an…
Editas Medicine, Inc. $90 Million Follow-On Offering
Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90…
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $6.25 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to…
Bristol-Myers Squibb Company $1.5 Billion Notes Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public…
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants to Purchase Common Shares
Davis Polk advised Auris Medical Holding AG on its $10 million public offering of 10,000,000 of its common shares and 10,000…
Hermes Pardini R$763 Million Initial Public Offering
Davis Polk advised the joint bookrunners in connection with the initial public offering by Hermes Pardini and the selling…
Coherus BioSciences, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of…
Davis Polk Advises McKesson Corporation on $1 Billion Notes Offering by Change Healthcare
Davis Polk advised McKesson Corporation in connection with the offering of $1 billion aggregate principal amount of notes…
Jounce Therapeutics, Inc. Initial Public Offering
Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9…
Davis Polk Advises Affimed on Its $18 Million Offering of Shares
Davis Polk advised Affimed N.V. on its $18 million public offering of 10,000,000 of its common shares. The underwriters have…